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Abstract
Etiology of hearing impairment (HI) is complex and comprises genetic and environ-
mental factors. Currently, the background of genetic hearing impairment is an area of 
intensive research and we are witnessing fast progress in this field. The story has begun 
in 1997 when the DFNB1 locus was discovered with GJB2 and GJB6 genes causative 
for almost 50% of cases of recessive, profound, prelingual hearing loss. Nowadays, we 
have much more possibilities for dissecting the reason of HI, but proper assessment 
of clinical symptoms is essential for selecting the most optimal diagnostic pathway. In 
the first stage, the detailed characteristic of hearing loss including its level established 
by pure tone audiometry (PTA) or auditory brainstem responses (ABR), age of onset, 
and other helpful features as progressive or no progressive type should be provided. 
Subsequently, the presence or absence of accompanying symptoms should be estab-
lished and followed by a detailed analysis of pedigree. In addition, modern assistive 
algorithms such as AudioGene, Face2Gene, and POSSUM are also discussed. Taking 
into account the variety of causative genes and pathogenic variants underling hearing 
loss, searching for causative genes, after exclusion of the DFNB1 variants, should be 
performed with multigenic panels based on next-generation sequencing technology.
Keywords: gene, pathogenic variant, phenotype, diagnostic, pedigree, next-generation 
sequencing
1. Introduction
The dynamic development of new DNA sequencing technologies in recent years has given 
us unprecedented insight into the information encoded in the human genome. Introduction 
of these techniques into a clinical practice has put the diagnosis of genetic disorders to a 
much more advanced level with a very high detection rate of pathogenic variants. Hearing 
loss (HL) has also greatly benefited from the technological revolution as it is a genetically 
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 heterogeneous condition with more than 100 different genes being involved in its pathogen-
esis, and novel genes are still being discovered (www.herediataryhearingloss.org; accessed 
10/2017). As compared to the strategy of sequential analysis of single genes, the application of 
high-throughput DNA sequencing has increased the diagnostic yield of genetic causes of HL 
by approximately four times [1].
At the same time, the technological advancements have brought us to a higher level of com-
plexity. Searching for HL-causing variants, often hundreds of genes have to be analyzed 
and we are flooded by huge amounts of information that are difficult to interpret [2]. It is 
partially overcome by still-improving computational tools and growing data from popu-
lation studies, but an indispensable part of better planning of genetic testing and under-
standing its results is the information gathered from a thorough clinical examination and 
family history. Sometimes, the primary clinical data collected prior to genetic testing do not 
completely match the phenotypic features that could be expected from molecular findings. 
In such cases, clinical reevaluation is needed to better delineate the phenotype and verify 
whether the identified genetic variants are indeed responsible for the observed clinical fea-
tures [3, 4].
2. Pedigree construction and analysis
The fundamental and basic element of genetic evaluation in the consultation room is the 
creation of a precise and accurate family pedigree based on the detailed medical interview. 
A genetic pedigree is a diagram of genetic relationship enriched with an information about 
health history, which allows to easily trace the transmission of symptoms, estimate whether 
symptoms may be caused by genetic reason, and evaluate the risk for other family mem-
bers (including unborn) of an inherited disorder. Although in the archival literature, readers 
may encounter many different systems of constructing pedigrees [5], the current, uniform, 
and precise guidelines in this area should be followed and applied in both clinical practice 
and publications. Taking into account the dynamic rise of genetic knowledge within the last 
years, triggered by new technologies such as next-generation sequencing (NGS), clinicians 
and scientists should be familiar with preparation and interpretation of a pedigree. This 
allows a proper interpretation of medical and genetic information of the studied family. At 
the time of writing, an authority dealing with the standardization of the terminology used 
to describe a pedigree is the National Society of Genetic Counselors (NSGC, http://www.
nsgc.org) established in 1979 in the United States of America (USA), with its two official 
journals: “Journal of Genetic Counseling” and “Perspectives in Genetic Counseling.” The 
Pedigree Standardization Work Group (PSWG) operating within the NSGC established uni-
fied recommendations for standardized human pedigree in 1995 [6, 7], and updated it in 
2008 [8]. Regarding the fact that no alternative comprehensive, analogous recommendations 
have been proposed, along with lack of critical comments on the proposed system, the PSWG 
established rules have become an accepted and international symbolic language of human 
genetic clinicians and researchers.
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The most commonly used pedigree symbols, definitions, and abbreviations in compliance 
with the PSWG revised recommendations are presented in Figure 1.
With the symbols listed in Figure 1, a family tree should be created according to the following 
rules:
• At the beginning, a shaded symbol (square for male, circle for female) denoting the pro-
band (an affected person from a family who came for a medical consultation as first) should 
be placed. In the bottom left corner, an arrow and letter “P” should be placed to uniquely 
mark that this individual is the proband.
• Above the symbols for proband’s, ancestors starting with parents should be placed. The 
symbol denoting male partner should be placed to the left of the female’s one if possible. 
Furthermore, symbols denoting both parents should be connected by a horizontal line (re-
lationship line) and doubled if the parents are consanguineous. The line of descent should 
be placed in the middle of the horizontal line, which connects parents with the offspring 
(sibship line).
• All symbols representing siblings should be placed in the birth order starting from the left 
side, at the same height as the proband’s symbol. Vertical lines (individual’s line), link-
ing symbols to the horizontal line (sibship line) above the symbols, must be placed for all 
 siblings’ symbols.
• According to the above-described rules, symbols representing all remaining family mem-
bers should be placed and joined with the appropriate lines.
• Some additional, useful information such as disease, age, age at death, initials, or the first 
name may be placed below appropriate symbols.
The pedigree line definitions and rules of placing them within the pedigree are presented in 
Figure 2.
Additional most common symbols, rules, and family situations are gathered in Figure 3.
Since drawing pedigrees, especially for large families, is complicated and time consuming, it 
is worth to use computer programs that facilitate and accelerate this task. There are many pro-
fessional and public tools, which are useful in the process of creating accurate family diagrams 
for both, clinical and educational purposes, e.g., Genial Pedigree Draw (http://www.pedi-
greedraw.com/), Progeny Online Pedigree Tool (http://www.progenygenetics.com/online-
pedigree/), and CeGaT Pedigree Chart Designer (http://www.cegat.de/en/for-physicians/
pedigree-chart-designer/).
Understanding the elementary rules of inheritance is the key to appreciate how traits or dis-
eases are passed on within a family. It should be reminded here that every individual has two 
copies of almost every gene localized on chromosome (autosome), one of them derives from 
biological mother and the second one from biological father. The situation is different in case 
of sex chromosomes—every male has only one X (inherited from mother) and Y chromosome 
(inherited from father). The Y chromosome is transmitted in its entirety exclusively from 
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Figure 2. Definition of pedigree lines.
Figure 1. Most common pedigree symbols according to Bennett et al. [8].
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father to son. In contrast, every female has two X chromosomes (inherited from both parents) 
[9]. Another derogation from basic inheritance rules is mitochondrial inheritance, in which 
the entire independent small genome is passed only from mother to offspring [10]. Typically, 
Figure 3. Symbols useful in uncommon clinical situations.
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there are four most common inheritance patterns, depending on the genomic localization 
and influence on the protein function of pathogenic variants or genes i.e., autosomal domi-
nant (AD), autosomal recessive (AR), sex-linked, and mitochondrial [11]. Diseases caused by 
pathogenic variants localized in a single gene are mostly inherited in an AD or AR pattern 
and are referred to as Mendelian inheritance (tribute to Gregor Mendel, who first noted this 
pattern in pea plants).
The AD mode of inheritance occurs when a single copy of the disrupted (mutated) gene is 
causative of the disease. It should be emphasized that for AD disorders, a variety of inter 
and intrafamilial variability of symptoms may occur. Nevertheless, there are few substan-
tial features, which make this mode of inheritance rather simple to distinguish. Dominantly 
inherited genetic diseases tend to occur in every generation of a family, they affect males and 
females equally; furthermore, the disorder may be transmitted from males and females. The 
risk for offspring to inherit the pathogenic variant is 50%. Due to the variability of symptoms 
severity, characteristic for this type of inheritance, the risk of becoming symptomatic may 
be less than 50%. A typical family tree representing the AD mode of inheritance is shown in 
Figure 4.
The AR type of inheritance requires two disrupted copies of a gene for a disease to occur. 
Thus, both parents of an affected individual are obligatory asymptomatic carriers (due to an 
assumption that heterozygotes do not manifest a disease). Furthermore, the symptoms are 
not typically seen in every generation. AR diseases are much more common in offspring of 
consanguineous pairs (which is evident within small, isolated populations e.g., Icelanders, 
Bedouins, or Amish [12]. In contrast to the AD inheritance mode, affected individuals present 
more consistent clinical picture. The risk for offspring to inherit both pathogenic variants is 
25%, whereas the risk to inherit one heterozygous variant is 50%. It should be also noted that 
all children of an affected parent and a noncarrier partner, regardless of their gender, will be 
obligate carriers. A typical family pedigree illustrating the AR mode of inheritance is shown 
in Figure 5.
A sex-linked mode of inheritance consists of three subtypes: X-linked dominant (XLD), 
X-linked recessive (XLR), and Y-linked. Whereas the Y chromosome contains very limited 
Figure 4. Pedigree of a family with the AD pattern of inheritance.
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number of genes and there are only few Y-linked disorders, none of them related to hearing 
and speech disorders, this type of inheritance will not be described here. The XLD and XLR 
type of inheritance relate to genes located on the X chromosome, and for the occurrence of 
XLD symptoms, only one copy of a disrupted X-linked gene is required. XLD diseases usu-
ally manifest very severely in males, which may lead to spontaneous abortion or neonatal 
death. The characteristic feature for this type of inheritance is that there is no transmission of 
the disease from male to male, and all of the female offspring of affected male will inherit the 
pathogenic variant and the disease. A characteristic family tree for the XLD mode of inheri-
tance is shown in Figure 6.
Figure 5. Two typical family trees representing the AR type of inheritance.
Figure 6. Exemplary pedigree of a family with the XLD type of inheritance.
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For an XLR disease to occur in females, both copies of a gene must be impaired. Characteristic 
features for an XLR inheritance mode are affected males, but an extremely low number or no 
affected females, in every generation. A distinct feature of the XLR inheritance pattern is that 
the pedigree tree shows no male to male transmission of the disease. All males harboring a 
pathogenic variant in an X-linked gene present severe symptoms of the disease, whereas car-
rier females are in general unaffected or present significantly less severe symptoms. A typical 
family tree representing the XLR mode of inheritance is shown in Figure 7.
Although within small families, which currently are very common, especially in European 
countries, the recognition of an X-linked inheritance pattern is rather challenging and remains 
unknown until the results of genetic testing [4].
The mitochondrial mode of inheritance has distinctive features differentiating it from oth-
ers. Briefly, this unique features come directly from mitochondrial DNA (mtDNA) specific-
ity: mtDNA is a small, independent, circular genome; furthermore, an average human cell 
contains up to 1000 mitochondria and in every mitochondrion several copies of the mtDNA 
genome may be present. If all mitochondria in a given individual contain an mtDNA variant 
it is defined as homoplasmy. In contrast, heteroplasmy indicates the coexistence of more than 
one mtDNA type within an individual. As all mitochondria of offspring are of maternal ori-
gin, the pathogenic variants localized within mtDNA are exclusively passed from mother to 
children and they may affect males and females equally. Consistently, males do not transmit 
the mtDNA disorders to their offspring. A representative family tree demonstrating mito-
chondrial mode of inheritance is shown in Figure 8.
Figure 7. Pedigree of a family with the XLR pattern of inheritance.
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It should be emphasized that in many cases distinction between the mitochondrial and AD 
inheritance is a difficult task based only on the family tree analysis.
3. Nonsyndromic hearing loss
It has to be stressed that all patients with a positive family history of HL should be referred for 
genetic counseling. Over generations, an inherited disorder automatically raises a suspicion 
of a genetic underlying cause. A careful analysis of a family pedigree enables to identify or to 
presume the mode in which hearing impairment is inherited. This in turn is an important step 
in directing genetic testing at specific genes that are causally involved in the pathogenesis of 
autosomal dominant, recessive, X-linked, or mitochondrial HL. In case of marriages between 
individuals with hearing impairment or between individuals coming from families with hear-
ing impairment, the family pedigrees should be analyzed especially carefully. In the offspring 
of such couples, different HL causative variants of different genes may be found. Interestingly, 
in a study of 80 deafness genes, the DNA samples of HL patients were significantly enriched 
in potentially pathogenic variants [13]. One possible explanation of the phenomenon may the 
above-mentioned marriages between hearing impaired individuals. Attention should also be 
paid to the consanguinity between parents, which is common in certain populations. Looking 
for a genetic cause of HL in offspring of a consanguineous couple, the autosomal recessive 
mode of inheritance with pathogenic variants in a homozygous state is primarily expected.
A diagnostic challenge represents an HL patient without other affected family members, also 
referred to as a sporadic case. Here, a family history of HL is negative and a genetic cause is 
strongly suspected after exclusion of environmental factors, such as prenatal infection (with 
toxoplasmosis, rubella, cytomegalovirus, and herpesvirus—“TORCH” organisms), postnatal 
infections (mainly bacterial meningitis, mumps), prematurity, traumatic injury, blood vessels 
Figure 8. Pedigree of a family with mitochondrial mode of inheritance.
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or autoimmune disease, Meniere’s disease, acoustic neuroma, exposure to chemical agents, or 
noise that may be responsible for HL development. While describing HL, four major terms 
related to its presentation such as (I) the age of onset, (II) the type, (III) the degree of HL, and (IV) 
stability are usually used. The onset of HL can be congenital, prelingual (before a child devel-
ops speech), postlingual (after the acquisition of speech and language, usually after the age of 
six), adult-onset or age-related late-onset (presbyacusis). The different types of HL (conductive, 
sensorineural, or mixed) indicate which part of the ear is affected. Genetically determined HL is 
usually bilateral although families with asymmetric and unilateral HL are also reported [14, 15].
It has been estimated that about 80% of prelingual HL results from genetic factors. It is most 
often inherited as an autosomal recessive feature without other accompanying medical prob-
lems The second most common inheritance pattern of prelingual HL is autosomal dominant 
(20%), while X-linked and mitochondrial constitute together approximately 1–1.5% [16]. Most 
of the reported families with nonsyndromic postlingual HL present an autosomal dominant 
pattern of inheritance. Currently, 36 different genes causally involved in autosomal dominant 
HL have been identified (www.herediataryhearingloss.org; accessed 10/2017) and only a few 
of them are associated with prelingual HL [17].
If hearing impairment represents an isolated finding that can be associated with abnormali-
ties of the middle and/or inner ear but is not accompanied by visible abnormalities of the 
outer ear or any other medical problems, it is referred to as nonsyndromic or isolated. The 
major cause of prelingual severe-to-profound autosomal recessive nonsyndromic HL in many 
populations are pathogenic variants of the GJB2 gene. The GJB2 and GJB6 genes, contained 
within the DFNB1 locus, should be tested in the first line in patients with nonsyndromic bilat-
eral sensorineural HL of the prelingual onset [18].
Pathogenic GJB2 variants are also identified as the second most frequent cause of mild-to-
moderate autosomal recessive HL. The most common causes of HL in this group of patients 
are pathogenic variants of the STRC gene and the third causative gene in this category is 
TECTA, but the prevalences vary among different ethnic groups [13, 19].
Discussing the genetic causes underlying partial deafness, defined as normal or slightly dete-
riorated thresholds involving low frequencies combined with profound HL in high frequen-
cies [20], pathogenic variants localized within mtDNA and TMPRSS3 should be considered 
for diagnostic purposes [21, 22]. Nevertheless, the contribution of other genes should be also 
taken into account.
Inheritance pattern Genes and loci involved
AD COCH (DFNA9), WFS1 (DFNA6/14/38), MYO6 (DFNA22), GJB2 (DFN3A), MYO7A 
(DFNA11)
AR GJB2 (DFNB1A), SLC26A4 (DFNB4), MYO15A (DFNB3), TMC1 (DFNB7/11), TMPRSS3 
(DFNB8/10), STRC (DFNB16)
X-linked POU3F4 (DFNX2), PRPS1 (DFNX1), SMPX (DFNX4), COL4A6 (DFNX6), AIFM1 (DFNX5)
Mitochondrial MT-TL1, MT-TK, MT-TS1, MT-TE, MT-RNR1
Table 1. Genes involved in the pathogenesis of hearing disorders grouped according to the type of inheritance—examples.
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Locus DFNB1, gene GJB2, inheritance type: AR Remarks
Truncating pathogenic 
variants (e.g., c.35delG)






Locus DFNB4, gene SLC26A4, inheritance type: AR Remarks
Nontruncating, 
pathogenic variants (e.g., 
p.Glu29Gln)
Enlarged vestibular aqueduct, 
vestibular dysfunction, Mondini 
malformation, early-onset, 
fluctuating HL [25]
Locus DFNA6/14/38, gene WFS1, inheritance type: AD Remarks
Nontruncating, 
pathogenic variants (e.g., 
p.Asp771His)
Postlingual, low-frequency HL, 
deteriorating with time [26]
Locus DFNX2, gene POU3F4, inheritance type: X-linked Remarks
Truncating pathogenic 
variants (e.g., p.Glu187*)
Congenital, profound, sensorineural 
HL (may be accompanied by a 
conductive component). Inner ear 
IP3 type malformation—comprises 
of enlarged internal auditory 
canal and vestibular aqueduct, 
underdeveloped
cochlear modiolus and 
malformations of the vestibule. 
Due to the inner ear malformation 
perilymphatic gusher may occur 
during inner ear surgery [4]
Gene MT-TS1, inheritance type: X-linked Remarks
Pathogenic variants (e.g., 
m.7511T>C)
Postlingual, high-frequency HL [27]
Table 2. Pedigrees and audiometric features characteristic for different genes and pathogenic variants causative of HL.
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Considering the significant contribution of genetic factors to HL and the recent guideline for 
clinical evaluation and etiologic diagnosis of HL, one may conclude that single-gene testing 
is justified if a specific genetic etiology of HL is suspected. If there are no specific clinical 
indications, testing for the DFNB1-related HL should be performed. If the investigations do 
not provide conclusive results, HL genes may be analyzed by the NGS approaches such as 
multigene panels, whole exome or whole genome sequencing [16]. All known nonsyndromic 
deafness loci (locus denotes the position in the genome linked with the disease) are labeled 
as DFN (DeaFNess) and classified according to the type of inheritance (DFNA: autosomal 
dominant; DFNB: autosomal recessive; DFNX: X-linked) followed by a number indicating the 
order of locus discovery. In Table 1, some of the most common HL causative loci are gathered.
As it was previously stated, HL is a genetically heterogenous disease; nevertheless, there are 
some common, characteristic features, which may be a valuable asset in the process of dissect-
ing the genetic reason of HL. Examples of pedigrees, characteristic audiometric features, and 
additional remarks for some common HL genes are shown in Table 2.
Despite quite a large number of genes causative for HL, the first step in the diagnostic 
approach should be the analysis of the DFNB1 locus, as the testing is inexpensive and fast 
[28]. Apart from obvious clinical indications, such as IP3 malformation for the POU3F4 gene 
analysis, the remaining cases should be rather streamed to wide, multigenic analysis.
4. Syndromic hearing loss
In contrast to the nonsyndromic hearing impairment, the syndromic hearing impairment is 
defined as a part of a syndrome, and it is associated with malformations of the external ear, 
malformations of other organs or other medical problems. HL is identified in more than 400 
different syndromes [29]. The most common type of autosomal dominant syndrome with sen-
sorineural HL is Waardenburg syndrome (WS types 1-4; OMIM#193500, #193510, #148820, and 
#277580), an auditory-pigmentary syndrome caused by pathogenic variants in PAX3, MITF, 
EDNRB, EDN3, or SOX10 genes and characterized by the presence of pigmentary anomalies 
of skin, hair, and eyes. The second most common are branchiootorenal spectrum disorders 
(OMIM#113650, #610896 #602588, #166780), where conductive/sensorineural HL is accompa-
nied by branchial cleft cysts or fistulas, malformations of outer ear, preauricular pits, and renal 
anomalies resulting from pathogenic variants in EYA1, SIX1, or SIX5. The third most common 
cause of autosomal dominant syndromic hearing impairment is neurofibromatosis type 2  
(NF2, OMIM#101000), a multiple neoplasia syndrome with HL secondary to the usually bilat-
eral vestibular schwannomas (acoustic neuroma) and other tumors of the central nervous sys-
tem (meningioma, schwannoma, glioma, or neurofibroma). NF2 is caused by heterozygous 
pathogenic variants in a gene-encoding neurofibromin-2 (NF2 gene) [30].
The Stickler syndrome (STL) is a connective tissue disorder with eye findings (high myo-
pia, vitreoretinal degeneration, retinal detachment, and cataract) being the most constant 
traits. Other features are sensorineural or conductive HL, midline clefting (cleft palate, 
bifid uvula), Pierre Robin sequence, flat midface, mild spondyloephiphyseal dysplasia, and 
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early-onset osteoarthritis [31]. Currently, four types of STL syndrome are distinguished—
autosomal dominant STL1 (OMIM#108300) and STL2 (OMIM# 604841) caused by patho-
genic variants in COL2A1 and COL11A1, and autosomal recessive STL4 (OMIM#614134) 
and STL5 (OMIM#614284) due to pathogenic variants in COL9A1 and COL9A2 genes, 
respectively. The Usher syndrome (USH) is a combination of HL and visual impairment as 
a consequence of retinitis pigmentosa. The autosomal recessive condition is classified into 
three types: USH1 (OMIM#276900) with severe-to-profound deafness and defective ves-
tibular function, USH2 (OMIM#276901) with mild-to-severe hearing impairment and nor-
mal vestibular function and USH3 (OMIM#276902) with progressive postlingual HL and 
vestibular dysfunction. Pathogenic variants in one of six genes (MYO7A, USH1C, CDH23, 
PCDH15, USH1G, or CIB2) may lead to USH1 [32], in one of three genes (ADGRV1, WHRN, 
or USH2A) to USH2 and in one of two genes (CLRN1 or HARS) to USH3. The second most 
common autosomal recessive syndrome with sensorineural HL is the Pendred syndrome 
(PDS, OMIM#274600), characterized by severe-to profound deafness that is congenital or 
develops in early childhood and euthyroid/hypothyroid goiter that arises in early puberty 
or adulthood. It is associated with developmental abnormalities of the cochlea (Mondini 
dysplasia or enlarged vestibular aqueduct) that can be diagnosed by a CT examination 
of temporal bones. The cause of the PDS is pathogenic variants in the SLAC26A4 gene 
encoding an anion transporter named pendrin. The third most common autosomal reces-
sive syndrome with deafness is the Jervell and Lange-Nielsen syndrome (JLN), which 
is marked by congenital profound sensorineural HL and prolongation of the QT interval 
(corrected QT (QTc) > 440 msec), syncopal episodes due to ventricular arrhythmias and 
a high risk of sudden death. In patients with JLNS1 (OMIM#220400) pathogenic variants 
in KCNQ1 and in patients with JLNS2 (OMIM#612347) pathogenic variants in KCNE1 are 
found.
The two following autosomal recessive syndromic forms of HL represent rare metabolic dis-
orders that, however, should not be missed out as their symptoms may resolve by appropri-
ate treatment and dietary modifications. The Biotinidase deficiency (BTD, OMIM#253260) 
is a form of multiple carboxylase deficiency characterized by primarily neurologic (seizures, 
hypertonia, developmental delay, ataxia) and cutaneous (skin rash, dermatitis, alopecia) 
features. Patients lose vision and three-fourth of those who become symptomatic have some 
degree of HL. Laboratory findings show organic aciduria, mild hyperammonemia, and bio-
tinidase deficiency. The BTD begins usually within the two first years of life and results from 
recessive pathogenic variants in the BTD gene. Treatment with biotin resolves neurologic 
and cutaneous manifestations, while HL and optic atrophy are usually irreversible.
The Refsum disease (OMIM#266500) is an inborn error of lipid metabolism with anosmia and 
early-onset retinitis pigmentosa being two universal findings. Other variable clinical features 
include neuropathy, ataxia, progressive severe HL, ichthyosis, cardiac, and skeletal (metacarpals/
metatarsals shortening) involvement. Increased serum concentration of phytanic acid establishes 
the diagnosis. The symptoms present an insidious onset usually during the late first through 
third decades of life. Causative recessive variants are found in the PHYH and PEX7 genes. In the 
medical care, diet modifications aimed at reduction of chlorophyll from the diet (exclusion of 
green vegetables (phytanic acid), and animal fat (phytol), and plasmapheresis) are used.
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Syndromic X-linked HL is represented by the Alport (OMIM#301050) and Mohr-Tranebjaerg 
(MTS, OMIM#304700) syndromes. The Alport syndrome is characterized by glomerulone-
phropathy leading to progressive renal failure, varying severity of progressive sensorineural 
HL (occurs typically after 10 years of age and affects mainly high frequencies), and variable 
ocular anomalies. In 85% of patients with Alport syndrome, dominant pathogenic variants in 
the COL4A5 gene on the X chromosome are found. Approximately 15% of patients develop 
Alport syndrome due to recessive variants in the COL4A4 or COL4A3 genes, cases with auto-
somal dominant inheritance, have also been occasionally reported.
In the Mohr-Tranebjaerg syndrome, also known as progressive deafness syndrome with 
blindness, dystonia, fractures and mental deficiency, progressive pre- or postlingual sensori-
neural deafness occurs in the early childhood and is a presenting symptom. MTS is caused by 
recessive variants of the TIMM8A gene.
Mutations in the mitochondrial genome can lead to HL that is an isolated feature or part 
of genetic syndrome, i.e., mitochondrial encephalomyopathy, lactic acidosis, and stroke-like 
episodes (MELAS), myoclonic epilepsy with ragged-red fibers (MERFF) or Kearns-Sayre syn-
drome (KSS), a mitochondrial myopathy, characterized by ptosis, ophthalmoplegia, muscle 
weakness, cerebellar ataxia, diabetes mellitus, and/or endocrinopathies [33]. Aminoglycoside 
ototoxicity has been associated with pathogenic variants in MT-RNR1 [34]. Pathogenic variant 
m.3243A > G in the MT-TL1 gene, which is causative of MELAS, was found in patients with 
diabetes mellitus and HL or HL exclusively [35]. The data raise questions on mitochondrial 
variant penetrance, tissue specificity, and heteroplasmy level.
5. Assistive algorithms
Regarding the heterogeneity of genetically related HL, the precise evaluation of its cause is 
a challenging task. Apart from some, rather rare, unquestionable phenotypic manifestations, 
many of the cases of possibly genetically related HL (syndromic and nonsyndromic) are hard 
to distinguish. It should be noted that there is a group of useful, assistive algorithms, which 
are helpful for both: establishing the diagnosis and targeting a diagnostic approach.
The Face2Gene (http://suite.face2gene.com/) is a collection of phenotyping applications, which 
enable accurate and comprehensive assessment of a patient based on characteristic dysmor-
phic facial features. As the variations in the face and skull are very common and are present in 
about 40% of genetic disorders, they are very useful in identification of the disorder. Briefly, 
the picture of patient face is uploaded to an application, than the quantification of the similarity 
is calculated with the usage of the algorithm database. The result is the list of syndromes with 
analogous morphology. The algorithm Face2Gene is accessible free of charge to all healthcare 
specialists.
The AudioGene (http://audiogene.eng.uiowa.edu/) predicts the genes underling autosomal 
dominant nonsyndromic hearing loss (ADNSHL) based on the audiometric data. This algo-
rithm also takes into account the age of the patient, which is essential in the ADNSHL study 
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due to characteristic deterioration of hearing during patient’s life. The algorithm is based on the 
computational analysis of specific audiometric data deposited in the database. Furthermore, 
the machine-learning method is applied to select and prioritize possibly causative genes for 
pathogenic variant screening [36, 37].
The Pictures of Standard Syndromes and Undiagnosed Malformations (POSSUM) (https://
www.possum.net.au/) is a comprehensive dysmorphology database designed for the diagno-
sis of multiple malformations, metabolic, teratogenic, chromosomal, and skeletal syndromes 
as well as their images. This database consists of information on over 4000 different syn-
dromes and searching is based on the selected features and results in a specific list of possible 
diagnoses [38].
6. Next-generation sequencing technology in dissecting the 
background of hearing loss
In almost all genetically related diseases (included hearing impairment), there is a need for 
tailored diagnostic strategies in searching for their molecular background. The milestone in 
this research area was the development of the method for the DNA sequencing by Frederick 
Sanger in 1975 [39]. Whereas the direct sequencing (called also Sanger sequencing—tribute to 
its inventor) allows to debunk the molecular cause of disease in a limited number of genes, 
e.g., when HL background analyses were limited to the GJB2 gene, there was a significant 
gap in our knowledge and diagnostic capabilities. This gap has been filled out by introduc-
ing NGS technology, also called massive parallel sequencing (MPS) or high-throughput DNA 
sequencing. The NGS developed over the last decade has revolutionized the genetic research 
and diagnostic practice, mainly because of reducing costs and time of DNA sequencing. This 
technology gives a unique opportunity to analyze in one experiment the sequence of more 
than 1 million base pairs, thus sequencing of the whole genome or thousands of genes simul-
taneously in a few days has become possible [40]. The most commonly used forms of NGS 
in searching for pathogenic variants underling HL are whole exome sequencing (WES) and 
multigene panels.
An undisputable advantage of the WES is the possibility of simultaneous sequencing of the 
whole coding DNA sequence (protein coding part within all human genes ~20,000) regardless of 
the disease studied. This makes WES a universal test for almost all known genetic diseases. The 
multigene panel sequencing is a more economical solution, especially dedicated for the diag-
nostic purpose. It should be noted that with the panel sequencing, only already known genes 
associated with a given disease are analyzed. Although the targeted NGS has many advantages, 
whole-genome sequencing (WGS) is still the state of art approach with its high cost representing 
a main drawback. The application of high-throughput DNA sequencing methods generates a 
vast amount of information, which accelerated the discovery of new, causative genes for many 
diseases. Also in the field of genetically related HL, with the NGS technology, novel genes have 
been discovered for all modes of inheritance described above. The important, newly discov-
ered genes causative of recessive HL are: ADCY1, BDP1, SYNE4, ELMOD3, CABP2, GRXCR2, 
OTOGL, TPRN, and TSPEAR. For dominant HL, the CEACAM16, P2RX2, and OSBPL2 genes 
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were revealed, also gene for the DFNX4 locus (i.e., SMPX) was identified. Another remarkable 
achievement obtained by the NGS technology is the identification of genes incorrectly classified 
as pathogenic, the examples of such events are: MYO1A and RAB40AL [41–43].
For the clinical diagnostic purpose, there are many commercial tests based on NGS, which dif-
fer in technologies and numbers of genes included. Heretofore, at least 20 commercially avail-
able tests, based on the NGS technology, focused on genetically related HL may be applied 
[1]. Due to the constant reduction of costs and availability, diagnostic approach based on 
the NGS technology in the nearest future will become a standard, which will significantly 
improve the level of patient care.
Index of technical terms
Autosomal dominant inheritance (AD)—type of Mendelian inheritance of a trait in which 
a defective copy of a gene (localized on autosome) dominates over the normal one. For the 
symptoms to occur, presence of only one defective copy is sufficient.
Autosomal recessive inheritance (AR)—type of Mendelian inheritance of a trait in which 
two copies of defective gene (localized on autosomes) are required in order for the disease to 
develop.
DFNB1 locus—most common locus causative for nonsyndromic hearing loss, containing 
GJB2 and GJB6 genes.
Direct sequencing—a technology allowing to determine the sequence of nucleotides in DNA 
invented in 1977 by Frederic Sanger and Alan R. Coulson, based on the chain-dideoxy termi-
nator method, also called Sanger sequencing.
Genetic pedigree—illustration of genetic relationship of a family, including information 
about health history of the family members.
Heteroplasmy—coexistence of more than one mtDNA type within an individual.
Homoplasmy—presence of a uniform type of mtDNA within an individual.
Mendelian inheritance—type of transmission of genes according to Gregor Mendel’s set of 
laws, also called classical inheritance. Mendelian inheritance comprises of autosomal domi-
nant, autosomal recessive, and X-linked type of inheritance.
Mitochondrial DNA (mtDNA)—small circular genome localized in the mitochondria.
Mitochondrial inheritance—non-Mendelian type of inheritance, occurring when a defective 
gene is located within the mitochondrial genome, inheritance of a trait encoded by this gene 
takes place exclusively from mother to offspring.
Next generation sequencing (NGS)—also known as high-throughput sequencing, a technol-
ogy allowing to establish the sequence of DNA larger than 1 million base pairs in a single 
experiment.
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Nonsyndromic deafness—deafness not associated with pathological symptoms/signs from 
other systems.
Partial deafness—hearing loss assessed by an audiometric test as a normal or little elevated 
hearing threshold within low frequencies and significantly raised hearing threshold in high 
frequencies.
Post-lingual hearing loss—hearing loss with late onset (after speech development).
Prelingual hearing loss—hearing loss with early onset (before speech development).
Sex-linked inheritance—type of the Mendelian inheritance of a trait in which the defective 
gene is located on X or Y chromosome.
Syndromic deafness—deafness as a part of a syndrome i.e., associated with pathological 
symptoms/signs from other organs.
Whole exome sequencing (WES)—approach based on NGS technology, allowing to sequence 
all protein-coding regions (exons).
Whole genome sequencing (WGS)—approach based on NGS technology allowing to analyze 
the whole genome DNA sequence.
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